Cocrystal Pharma, Inc.

9 patents currently held · Updated Nov 14, 2026

5 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Mar 2036

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Mar 12, 2027
The maintenance fee for Combination therapy for treatment of HCV (US 11,752,166) comes due Mar 12, 2027. Unpaid by Sep 13, 2027, it lapses early.
1 fee due May 5, 2027
The maintenance fee for Inhibitors of hepatitis C virus polymerase (US 10,464,914) comes due May 5, 2027. Unpaid by Nov 5, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 9 of 9

Patent	Title	Status	Expires	Confidence
US 10,464,914	Inhibitors of hepatitis C virus polymerase In force Term ends Mar 23, 2036 · From the USPTO record	In force	Term ends Mar 23, 2036	From the USPTO record
US 11,014,941	Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication In force Term ends Apr 24, 2038 · From the USPTO record	In force	Term ends Apr 24, 2038	From the USPTO record
US 11,752,166	Combination therapy for treatment of HCV In force Term ends Jul 14, 2039 · From the USPTO record	In force	Term ends Jul 14, 2039	From the USPTO record
US 12,037,333	Pyridopyrazine and Pyridotriazine Inhibitors of Influenza Virus Replication In force Term ends Mar 30, 2041 · High confidence	In force	Term ends Mar 30, 2041	High confidence
US 12,156,876	Formulations of Influenza Therapeutics In force Term ends Jan 21, 2042 · High confidence	In force	Term ends Jan 21, 2042	High confidence
US 12,357,631	Pyrrolo[2,3-B]pyridin derivatives as inhibitors of influenza virus replication In force Term ends Mar 10, 2042 · From the USPTO record	In force	Term ends Mar 10, 2042	From the USPTO record
US 12,233,066	Combinations of inhibitors of influenza virus replication In force Term ends Jun 26, 2042 · From the USPTO record	In force	Term ends Jun 26, 2042	From the USPTO record
US 12,565,488	Inhibitors of Influenza Virus Replication In force Term ends Aug 19, 2042 · High confidence	In force	Term ends Aug 19, 2042	High confidence
US 12,649,715	Inhibitors of Norovirus and Coronavirus Replication In force Term ends Dec 13, 2042 · High confidence	In force	Term ends Dec 13, 2042	High confidence

Also on record, not counted in the 9: 5 patents in force now held by others · 10 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

5 pending · 2 abandoned

List them